cyclacel
pharmaceuticals
release
third
quarter
financial
results
berkeley
heights
globe
newswire
cyclacel
pharmaceuticals
nasdaq
cycc
nasdaq
cyccp
cyclacel
company
biopharmaceutical
company
developing
innovative
medicines
based
cancer
cell
biology
announce
third
quarter
financial
results
wednesday
november
company
host
conference
call
live
webcast
eastern
daylight
time
day
conference
call
information
us
canada
call
international
call
us
canada
archive
international
archive
code
live
archived
conference
call
live
archived
webcast
please
visit
corporate
presentations
page
cyclacel
website
webcast
archived
days
audio
replay
days
cyclacel
pharmaceuticals
cyclacel
pharmaceuticals
biopharmaceutical
company
developing
innovative
cancer
medicines
based
cell
cycle
transcriptional
regulation
dna
damage
response
biology
transcriptional
regulation
program
evaluating
fadraciclib
solid
tumors
combination
venetoclax
patients
relapsed
refractory
aml
mds
cll
program
evaluating
inhibitor
advanced
leukemias
mds
patients
dna
damage
response
program
evaluating
oral
combination
sapacitabine
venetoclax
patients
relapsed
refractory
aml
mds
trial
ist
evaluating
oral
combination
sapacitabine
olaparib
patients
brca
mutant
breast
cancer
cyclacel
strategy
build
diversified
biopharmaceutical
business
focused
hematology
oncology
based
pipeline
novel
drug
candidates
additional
information
please
visit
statements
news
release
contains
certain
statements
involve
risks
uncertainties
could
cause
actual
results
materially
different
historical
results
future
results
expressed
implied
statements
statements
include
statements
regarding
among
things
efficacy
safety
intended
utilization
cyclacel
product
candidates
conduct
results
future
clinical
trials
plans
regarding
regulatory
filings
future
research
clinical
trials
plans
regarding
partnering
activities
factors
may
cause
actual
results
differ
materially
include
risk
product
candidates
appeared
promising
early
research
clinical
trials
demonstrate
safety
efficacy
later
clinical
trials
trials
may
difficulty
enrolling
cyclacel
may
obtain
approval
market
product
candidates
risks
associated
reliance
outside
financing
meet
capital
requirements
risks
associated
reliance
collaborative
partners
clinical
trials
development
commercialization
product
candidates
urged
consider
statements
include
words
may
would
could
believes
estimates
projects
potential
expects
plans
anticipates
intends
continues
forecast
designed
goal
negative
words
comparable
words
uncertain
list
description
risks
uncertainties
company
faces
please
refer
recent
annual
report
form
periodic
filings
cyclacel
files
securities
exchange
commission
available
statements
current
date
made
cyclacel
assumes
obligation
update
statements
whether
result
new
information
future
events
otherwise
contacts
company
paul
mcbarron
pmcbarron
investor
relations
russo
partners
llc
eric
ando
copyright
cyclacel
pharmaceuticals
rights
reserved
cyclacel
logo
trademarks
cyclacel
pharmaceuticals
inc
